Highlights From the 62nd ASH Annual Meeting and Exposition
First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A – BAY 2599023 has Broad Patient Eligibility and Stable and Sustained Long-Term Expression of FVIII
Steven W. Pipe, MD1, Francesca Ferrante, MD2, Muriel Reis3, Sara Wiegmann4, Claudia Lange5, Manuela Braun5, and Lisa A. Michaels6
1Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI
2Bayer, Basel, Switzerland
3Bayer, Sao Paulo, Brazil
4Bayer, Wuppertal, Germany
5Bayer, Berlin, Germany
6Bayer, Whippany, NJ
RELATED CONTENT
Interactive Webinars
Podcasts